ISLAND PHARMACEUTICALS LIMITED ILA IPO Analysis

From the prospectus, Company Presentations and Media articles

ISLAND PHARMACEUTICALS LIMITED

IPO Price 25c

Cash 7.5 mil

SOI 80 mil

Mcap 20 mil

EV 12.5 mil

SOLVING URGENT VIRAL DISEASE THREATS

• Island has repurposed ISLA-101, an antiviral oral drug to treat mosquito-borne viruses (eg dengue fever / Zika) and intends to complete Phase II studies with a significantly derisked clinical program
• Warming global climates are accelerating the presence of mosquito-borne viruses that can cause deaths in the US, Europe and Australia
• Island Initially targeting dengue diseases with unmet need. Targeting diseases, starting with dengue fever, with a significant unmet medical need and growing economic burden.
• Drug repurposing strategy. The lead compound, ISLA101, has been in 45 clinical trials demonstrating an excellent safety profile in thousands of patients.
• Phase II ready asset. Repurposing can save tens of millions of dollars and up to a decade of development time usually required to commercialize a new drug.
• Promising results to date Commercial upside Results in aggressive animal and human cellular models of dengue fever and Zika infections as well as data in a range of other flaviviruses.Potential ‘platform in a pill’ to treat tropical diseases.
• Approval of ISLA-101 by the US FDA could see company claim a Priority Review VoucherDr Paul MacLeman (AdAlta, several NASDAQ/TSX IPOs), Dr Anna Lavelle (Chair Medicines Australia), Dr David Brookes (recently sold Better Medical Group (GP roll-up) to P/E, Anatara, Factor Therapeutics) 9. Co-founder & US seed-investor, William (Bill) Garner, has a strong market following and has had considerable success in Race Oncology (RAC) – also a PRV-eligible company

Let's talk about the science behind ISLA 101

ISLA-101 PREVENTS VIRAL REPLICATION.ISLA-101 INHIBITS PROPAGATION OF FLAVIVIRUSES

To replicate, the virus needs to hijack the nucleus of the host cell. Studies demonstrated ISLA-101 prevents this so prevents virus replication.

Same mechanism of action for a therapeutic or prophylactic – either before or after exposure to the virus.

ISLA-101 targets protection of the nucleus

ISLA-101 BROAD ACTIVITY EVIDENT. DEMONSTRATED ACTIVITY AGAINST FLAVIVIRUSES IN FRESH HUMAN CELLS.

In in-vitro models using fresh human cells, ISLA-101 has demonstrated broad anti-viral activity • In animal models, ISLA-101 is protective in dengue fever and Zika.

In extremely lethal animal models, ISLA-101 was shown to prevent death in 70% of subjects.

Increasing concentrations of ISLA-101 prevent death induced by an otherwise lethal dengue fever infection.

PRIORITY REVIEW VOUCHER ELIGIBILITY.ISLA-101 INHIBITS THE STAGES AND PROTEINS OF FLAVIVIRUSES
ISLA-101 is eligible for Neglected Tropical Disease designation for the treatment of dengue fever.

This designation means ISLA-101 has the opportunity to be awarded a Priority ReviewvVoucher (PRV) from the FDA if first approved for dengue fever or Zika.

A PRV grants the holder an accelerated six-month review of a drug application by the FDA.

As PRVs are transferable, they are highly valuable to drug development companies with numerous precedents for sales to biotech and pharma companies.




Exceptionally High-Profile Global Advisory Board.

Prof. Stephen Thomas (Lead Principal Investigator for Pfizer/BioNTech global Phase II/III COVID-19 vaccine trials)Prof. Leigh Farrell (ex-Biota / Relenza, J&J Research, GBS Ventures)

Dr. Simon Tucker (ex-Biota – got Relenza through FDA)

Well-known & ASX-experienced Board.

Dr Paul MacLeman (AdAlta, several NASDAQ/TSX IPOs)

Dr Anna Lavelle (Chair Medicines Australia)

Dr David Brookes (recently sold Better Medical Group (GP roll-up) to P/E

Co-founder & US seed-investor, William (Bill) Garner, has a strong market following and has had considerable success in Race Oncology (RAC) – also a PRV-eligible company

Conclusion :

So Basically,

Island pharmaceutical( 12.5 Mil EV) will be the cheapest PRV eligible company On ASX . PRV-eligible drugs: Kazia Therapeutics KZA ($230m), Race Oncology RAC ($440m) ANTISENSE THERAPEUTICS LIMITED ANP ( 140 mil Mcap )

Island pharmaceutical( 12.5 Mil EV) will be the cheapest listed company on ASX which is trying to find a cure for infectious diseases. Anti-virals: Starpharma ($832m)

Island pharmaceutical( 12.5 Mil EV) will be the cheapest listed company on ASX which is trying to repurpose a drug.

Re-purposed drugs: Paradigm Biopharmaceuticals PAR ($620m), Race Oncology RAC ($430m)

IMO ,ILA is prised extremely cheap in comparison to its peers. Hence It will be Rerated sharply at open or in short term and can at least go to 100 mil Mcap on current fundamentals

And Once completion of phase 2 of ISLA 101 successfully, ILA can trade above 300 mil Mcap

I am expecting it to open 50c to 60c and It will quickly rush to $ 1 Mark.

DYOR

GLTAH

Cheers

Bhavdip